An exploratory, open‐label, investigator‐initiated study of interleukin‐17 blockade in patients with moderate‐to‐severe papulopustular rosacea

British Journal of DermatologyVolume 183, Issue 5 p. 942-943 Research Letter An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea A.M. Kumar, Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USASearch for more papers by this authorA.S. Chiou, Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USASearch for more papers by this authorY.H. Shih, orcid.org/0000-0003-2095-7064 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA Department of Dermatology, Taipei Medical University Shuang-Ho Hospital, New Taipei City, Taiwan Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanSearch for more papers by this authorS. Li, Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USASearch for more papers by this authorA.L.S. Chang, Corresponding Author alschang@stanford.edu orcid.org/0000-0002-2869-2147 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA Correspondence: Anne Lynn S. Chang. Email: alschang@stanford.eduSearch for more papers by this author A.M. Kumar, Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USASearch for more papers by this authorA.S. Chiou, Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USASearch for more papers by this authorY.H. Shih, orcid.org/0000-0003-2095-7064 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA Department of Dermatology, Taipei Medical University Shuang-Ho Hospital, New Taipei City, Taiwan Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanSearch for more papers by this authorS. Li, Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USASearch for more papers by this authorA.L.S. Chang, Corresponding Author alschang@stanford.edu orcid.org/0000-0002-2869-2147 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA Correspondence: Anne Lynn S. Chang. Email: alschang@stanford.eduSearch for more papers by this author First published: 04 May 2020 https://doi.org/10.1111/bjd.19172Citations: 6 Funding sources: This study was funded by an investigator-initiated research award from Novartis to A.L.S.C., and by a Stanford Medical Scholars Fellowship Program research award to A.M.K. A.L.S.C. was supported by a Dermatology Foundation Medical Dermatology Career Development Award. Y.H.S. was funded by Taipei Medical University and Stanford University. Conflicts of interest: A.L.S.C. is an investigator for other studies sponsored by Novartis, Galderma, Regeneron and Merck and has been an advisory board member for Novartis, Galderma, Regeneron and Merck. The other authors have no conflicts of interest to declare. This work was previously presented as a ‘Late Breaking’ poster (#LB1106) at the Society of Investigative Dermatology Annual Meeting 2019, Chicago, IL, USA. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume183, Issue5November 2020Pages 942-943 RelatedInformation